Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Cannabis Taboo Challenged By Neuraxpharm Campaign

CNS Specialist Launches Change For Health To Increase Medical Cannabis Awareness

Executive Summary

Neuraxpharm has launched its Change for Health campaign, which aims to increase awareness and bust misconceptions about the use of medical cannabis.

You may also be interested in...



Panaxia And Neuraxpharm Sign To Sell Medical Cannabis In The Czech Republic And Switzerland

Panaxia and Neuraxpharm have added the Czech Republic and Switzerland to their growing list of European markets for medical cannabis. Both countries have passed recent legislation to stimulate prescriptions of cannabis products.

Japan Moves To Lift Long-Standing Medical Cannabis Ban

Finally responding to pressure from domestic physicians, Japan has started discussions on the possible revision of long-standing regulations to allow the medical use of cannabis products, while putting in place strict measures to prevent illegal use or distribution.

Heightening Focus On Hemp, Cannabis, US FDA Hires Norman Birenbaum As Public Health Advisor

Hemp industry and private attorneys glad Birenbaum, who was the chief cannabis policy advisor to governors of New York and Rhode Island, given prominent role at FDA that could spur regulatory action.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel